Skip to main content

13.02.2024 | Research

Safety and outcome of treatment of latent tuberculosis infection in liver transplant recipients

verfasst von: Yun Woo Lee, Hyemin Chung, Sung-Han Kim, Heungsup Sung, Su-Min Ha, Eun-Kyoung Jwa, Dong-Hwan Jung, Deok-Bog Moon, Sung-Gyu Lee, Sang-Oh Lee

Erschienen in: Infection

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Liver transplant (LT) recipients have an increased risk of tuberculosis (TB), which is associated with higher mortality rates. This retrospective cohort study assessed the outcome and tolerability of screening and treatment of latent tuberculosis infection (LTBI) in LT recipients.

Methods

Between March 2020 and February 2022, all adult LT candidates at our institution were screened for LTBI. The candidates who tested positive for interferon-γ-releasing assay or met epidemiological or clinical-radiological criteria for LTBI were treated and monitored.

Results

Among the 857 LT recipients, 199 (23.2%) were diagnosed with LTBI, of which 171 (85.9%) initiated LTBI treatment. The median duration of follow-up was 677 days. Adequate LTBI treatment occurred in 141/171 (82.5%) patients and was discontinued prematurely in 30/171 (17.5%) patients. The most common reason for discontinuation was liver enzyme elevation (11/30, 36.7%), although only five discontinued treatment due to suspicion of isoniazid-associated hepatotoxicity. None of the LTBI-treated patients developed active TB during the follow-up period, while 3.6% (1/28) of untreated LTBI patients and 0.6% (4/658) of patients without LTBI developed TB.

Conclusion

These findings demonstrate that LTBI screening and treatment is a safe and effective strategy to prevent TB in LT recipients. However, monitoring for adverse events and liver enzyme elevation is recommended.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
8.
Zurück zum Zitat Holty JE, Gould MK, Meinke L, Keeffe EB, Ruoss SJ. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2009;15:894–906. https://doi.org/10.1002/lt.21709.CrossRef Holty JE, Gould MK, Meinke L, Keeffe EB, Ruoss SJ. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2009;15:894–906. https://​doi.​org/​10.​1002/​lt.​21709.CrossRef
9.
Zurück zum Zitat Korean Guidelines for Tuberculosis Fourth Edition, 2020. Korean Guidelines for Tuberculosis Fourth Edition, 2020.
22.
Zurück zum Zitat Fábrega E, Sampedro B, Cabezas J, Casafont F, Mieses M, Moraleja I, et al. Chemoprophylaxis with isoniazid in liver transplant recipients. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2012;18:1110–7. https://doi.org/10.1002/lt.23480.CrossRef Fábrega E, Sampedro B, Cabezas J, Casafont F, Mieses M, Moraleja I, et al. Chemoprophylaxis with isoniazid in liver transplant recipients. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2012;18:1110–7. https://​doi.​org/​10.​1002/​lt.​23480.CrossRef
23.
Zurück zum Zitat Olithselvan A, Rajagopala S, Vij M, Shanmugam V, Shanmugam N, Rela M. Tuberculosis in liver transplant recipients: experience of a South Indian liver transplant center. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2014;20:960–6. https://doi.org/10.1002/lt.23903.CrossRef Olithselvan A, Rajagopala S, Vij M, Shanmugam V, Shanmugam N, Rela M. Tuberculosis in liver transplant recipients: experience of a South Indian liver transplant center. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2014;20:960–6. https://​doi.​org/​10.​1002/​lt.​23903.CrossRef
24.
Metadaten
Titel
Safety and outcome of treatment of latent tuberculosis infection in liver transplant recipients
verfasst von
Yun Woo Lee
Hyemin Chung
Sung-Han Kim
Heungsup Sung
Su-Min Ha
Eun-Kyoung Jwa
Dong-Hwan Jung
Deok-Bog Moon
Sung-Gyu Lee
Sang-Oh Lee
Publikationsdatum
13.02.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-023-02161-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.